TGFBR2 and cancer: In line with the fact that cancer-initiating cells often show increased resistance to chemotherapy43–45, MDA-MB-231 cells pre-treated with TβRII+ EVs were more resistant to Paclitaxel (PTX) and Doxorubicin (Doxo) (Fig. 5f, g).